Managing CINV and Cachexia

Slides:

Advertisements

Similar presentations

Multimodal Management of Opioid-Induced Constipation

Advertisements

Bladder Cancer: A New Era in Treatment

The Nurse View: Management of Pancreatic Cancer

State of the Art in BRCA-Mutated Ovarian Cancer

Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.

Updated CINV Guidelines New Evidence for Change and Practical Issues

NOACs for Cancer-Associated Thrombosis:

Pharmacy Perspectives in Multiple Myeloma: Relapsed and/or Refractory Disease.

The Role of Anticholinergic Therapy in Moderate to Severe Asthma

Post-autologous Transplant Therapy for Hodgkin Lymphoma

Advanced NSCLC Without Actionable Mutations

Panelists. Panelists Drug-Coated Balloon for PAD.

Goals of Therapy for Patients With UC

BRCA, HRR Deficiency, and PARP Inhibitors

Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.

Thrombosis, Cancer, and NOACs

The Changing Therapeutic Landscape of CINV

At The Cutting Edge of Developments in the Management of Hyperkalemia

Program Goals. Program Goals Introduction Program Outline.

Emergency Management of NOAC Bleeding

Cancer Stem Cell Therapies in Gastrointestinal Cancers

PCP Perspectives Clinical Considerations in Hyperkalemia

Optimizing the Treatment of Recurrent/Metastatic SCCHN

Surveying the Safety of NOACs in the Real World

Program Goals. The Role of Chemotherapy in Improving Quality of Life in Advanced NSCLC.

Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?

Translating Atopic Dermatitis

Managing gBRCA-Positive Metastatic Breast Cancer

Moving Prostate Cancer Care Forward: Putting Lessons From New Orleans and Chicago Into Practice.

Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:

Individualizing Care in Ovarian Cancer

Patient Case: KC. Optimizing Treatment of Mild to Moderate Ulcerative Colitis: A Case-Based Perspective.

Antithrombotic Protection in CAD and HF

PCSK9 Inhibitors and Cardiovascular Outcomes

Program Goals. Single vs Dual HER2 Blockade for Metastatic HER2-Positive Breast Cancer.

A Better Solution For Cancer Patients With VTE?

Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Dos and Don’ts for High-Risk Elderly Patients With AF

Extraordinary Cases of VTE Prevention in Patients With Cancer

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

Updates on the Management of CINV From the 2014 June Congresses

Improving Outcomes in Psoriatic Arthritis

The Evolving Treatment Landscape in Atopic Dermatitis

Efficacy and Safety of Elbasvir/Grazoprevir in Treatment-Naïve patients with Chronic HCV GT 1, GT 4 and GT 6 Infection (C-CORAL): A Phase III Randomized.

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

5 Things You Need to Know About Hypoparathyroidism

Immune Checkpoint Inhibitors in Lung Cancer

Locally Advanced Lung Cancer

When Is Intrathecal Drug Delivery Appropriate?

Cancer-Associated Thrombosis

CAD and HF Often Coexist

Updates on the Prevention and Management of CINV

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Management of Advanced Pancreatic Adenocarcinoma

Managing Pulmonary Embolism Posthospital Discharge

Can Drug-Coated Balloons Be a Solution for Complex Peripheral Lesions?

On the Cusp: New Approaches for Multiple Myeloma

Introduction. Emerging Treatments for Thrombocytopenia in Adults With CLD Requiring Elective Invasive Procedures.

Reducing Risk for CV Outcomes

Patient Stories in PAH: Sequential Therapy in a FC II Patient

5 Good Minutes on Atrial Fibrillation-related Stroke

When Is Intrathecal Drug Delivery Appropriate?

Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations.

Tailoring Therapy in the Newly Diagnosed Patient With CLL

Real-World Evidence.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Panelists. Panelists Drug-Coated Balloon for PAD.

Translating Data From Trial to Practice

Presentation transcript:

Managing CINV and Cachexia

Program Goals

Concepts and Definitions for “Supportive Care” and “Palliative Care”

Supportive Care and Palliative Care

Supportive Care and Palliative Care (cont)

Supportive Care and Palliative Care (cont)

Cancer-Related Cachexia

Definition and Classification of Cancer-Related Cachexia An International Consensus

New Avenues of Investigation for Treatment of Cancer-Related Cachexia

ROMANA 1 and ROMANA 2 Phase 3 Study Design

ROMANA 1 and ROMANA 2 Efficacy Results: Co-Primary End Points

ROMANA 1 and ROMANA 2 Efficacy and Safety

Rolapitant

Rolapitant (cont)

Rolapitant: Regional Differences Subgroup Analysis of HEC Study

NEPA

NEPA (cont)

NEPA + DEX: Overall CR Rate by Gender/Age Pooled Analysis of Patients Receiving HEC in 3 Pivotal Studies

NEPA: Maintenance of Control Over 4 Cycles Pooled Analysis From 2 Studies

NEPA

Aprepitant in Children Phase 3 Trial Design

Aprepitant in Children (cont) Efficacy and Safety

Palonosetron vs Ondansetron in Children Phase 3 Trial Design

Palonosetron vs Ondansetron in Children (cont) Efficacy and Safety

Summary

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)